What did the FDA say about the sale of retatrutide to consumers?

In June, the U.S. Food and Drug Administration stated that sales of retatrutide and other unapproved versions of GLP-1 products to consumers are illegal and cannot lawfully be compounded.

Eli Lilly Sues Six Companies Over Alleged Illegal Sales of Experimental Obesity Drug Retatrutide

Q: Why did Eli Lilly file lawsuits against six companies over retatrutide?

Eli Lilly filed six lawsuits against U.S. companies—including compounding pharmacies, medical spas, and online sellers—for allegedly illegally selling black-market versions of its experimental obesity drug retatrutide, which remains unapproved by regulators and is still in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions.

Aug 12, 2026

Eli Lilly sued six companies for illegally selling unapproved black-market versions of its experimental obesity drug retatrutide, currently in Phase 3 trials. Highlighting safety risks, the firm urged regulators to curb illicit trade following intercepts of over 90,000 units.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026